Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis
Background & Aims Safety is a key consideration when choosing advanced therapies
(biologic agents and oral small-molecule inhibitors/modulators) in patients with inflammatory …
(biologic agents and oral small-molecule inhibitors/modulators) in patients with inflammatory …
Primary failure to an anti-TNF agent in inflammatory bowel disease: switch (to a second anti-TNF agent) or swap (for another mechanism of action)?
JP Gisbert, M Chaparro - Journal of Clinical Medicine, 2021 - mdpi.com
Background: About a third of patients with inflammatory bowel disease do not respond to
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …
Effectiveness and safety of adalimumab biosimilar SB5 in inflammatory bowel disease: outcomes in originator to SB5 switch, double biosimilar switch and bio-naïve …
LAAP Derikx, HW Dolby, N Plevris… - Journal of Crohn's …, 2021 - academic.oup.com
Abstract Background and Aims Multiple adalimumab [ADA] biosimilars are now approved for
use in inflammatory bowel disease [IBD]; however, effectiveness and safety data remain …
use in inflammatory bowel disease [IBD]; however, effectiveness and safety data remain …
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective …
C Rayer, M Nachury, A Bourreille, X Roblin… - BMC …, 2022 - Springer
Background No study has performed a face-to-face comparison of biologics after the failure
of the first anti-TNF agent in patients with Crohn's disease (CD). The aim of the study was to …
of the first anti-TNF agent in patients with Crohn's disease (CD). The aim of the study was to …
Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience
FS Macaluso, M Maida, M Grova… - Therapeutic …, 2021 - journals.sagepub.com
During past years, the increasing knowledge of molecular mechanisms of inflammatory
bowel disease (IBD) have led to the development of several targeted biological therapies …
bowel disease (IBD) have led to the development of several targeted biological therapies …
Switching within versus out of class following first-line TNFi failure in ulcerative colitis: real-world outcomes from a German claims data analysis
E Zhuleku, D Wirth, R Nissinen… - Therapeutic …, 2024 - journals.sagepub.com
Background: Biologic agents have demonstrated efficacy in treating ulcerative colitis (UC);
however, treatment failure to tumor necrosis factor inhibitors (TNFi) is common in the real …
however, treatment failure to tumor necrosis factor inhibitors (TNFi) is common in the real …
Comparative long-term drug survival of vedolizumab, adalimumab, and infliximab in biologic-naïve patients with ulcerative colitis
RS Dalal, EL McClure, J Marcus… - Digestive Diseases and …, 2023 - Springer
Background The comparative long-term survival of first-line biologics for UC and reasons for
drug discontinuation are poorly understood. We sought to compare the long-term drug …
drug discontinuation are poorly understood. We sought to compare the long-term drug …
Safety and efficacy of vedolizumab versus tumor necrosis factor α antagonists in an elderly IBD population: a single institution retrospective experience
BS Pabla, C Alex Wiles, JC Slaughter… - Digestive Diseases and …, 2021 - Springer
Background Vedolizumab is a monoclonal antibody used to treat inflammatory bowel
disease (IBD). There is little known about the safety and comparative efficacy of this agent in …
disease (IBD). There is little known about the safety and comparative efficacy of this agent in …
Second–Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real–World Propensity Score–Weighted Analysis
Background& Aims Tumor necrosis factor (TNF) antagonists often are used as first-line
medications to treat moderate to severe inflammatory bowel disease (IBD), but many …
medications to treat moderate to severe inflammatory bowel disease (IBD), but many …
Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA'comparison study
A Cassinotti, N Mezzina, A De Silvestri… - European Journal of …, 2022 - journals.lww.com
Continuous clinical remission with biologics in ulcerative c... : European Journal of
Gastroenterology & Hepatology Continuous clinical remission with biologics in ulcerative colitis …
Gastroenterology & Hepatology Continuous clinical remission with biologics in ulcerative colitis …